Page 2 - Igor Odintsov News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Igor odintsov. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Igor Odintsov Today - Breaking & Trending Today

Merus N.V.: Merus Announces Poster Presentations on Zenocutuzumab and MCLA-158 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Merus N.V.: Merus Announces Poster Presentations on Zenocutuzumab and MCLA-158 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United Kingdom , Ezraew Cohen , Rajan Khanna , Ernesto Wasserman , Alexandre Deshiere , Kees Bol , Igor Odintsov , Jeroen Lammerts Van Bueren , Shumei Kato , Lara Iglesias , Jan Gerlach , Patricia Martin Romano , Rocio Garcia Carbonero , Antoine Hollebecque , Viktoriya Stalbovskaya , Mohamed Bekkrada , Romel Somwar , Andrew Joe , Irene Brana , Cecile Geuijen , Marc Ladanyi , Mateo Bover , Josep Tabernero , Ron Schackmann , Exchange Commission , Virtual International Conference On Molecular ,

Elevation Oncology Announces the Presentation of New Preclinical Data in Pancreatic and Cholangiocarcinoma PDX Models on the Specific Inhibition of HER3 with Seribantumab to Block NRG1 Fusion Signaling

NRG1 gene fusion. The CRESTONE study is currently enrolling at sites across the United States.
Here we observed that NRG1 fusions activated HER3 and downstream signaling mediators such as AKT in a pancreatic cell line, said Igor Odintsov, MD, Research Fellow at MSK and lead author of the poster presentation. Treatment with seribantumab was able to inhibit phosphorylation of the activated HER3 and AKT in the same cell line, and subsequent treatment of an
APP-NRG1 fusion-positive pancreatic PDX model with seribantumab robustly inhibited tumor growth at clinically achievable doses.
Regressions were observed in all mice treated with 10 mg/kg BIW seribantumab, equivalent to a clinical dose of 2.6 g seribantumab in humans by allometric scaling. As in prior analysis in lung and ovarian ....

United States , Shawnm Leland , David Rosen , Igor Odintsov , Marc Ladanyi , Clinical Cancer Research , Elevation Oncology , Memorial Sloan Kettering , American Association , Cancer Research Virtual Annual Meeting , Research Fellow , Chief Executive Officer , ஒன்றுபட்டது மாநிலங்களில் , டேவிட் ரோஸன் , மருத்துவ புற்றுநோய் ஆராய்ச்சி , உயரம் புற்றுநோயியல் , நினைவகம் ஸ்லோன் கெட்டரிங் , அமெரிக்கன் சங்கம் , புற்றுநோய் ஆராய்ச்சி மெய்நிகர் ஆண்டு சந்தித்தல் , ஆராய்ச்சி சக , தலைமை நிர்வாகி அதிகாரி ,

Elevation Oncology Announces Clinical Cancer Research Publication Highlighting the Specific Inhibition of HER3 by Seribantumab in Preclinical NRG1 Fusion Models

Elevation Oncology Announces Clinical Cancer Research Publication Highlighting the Specific Inhibition of HER3 by Seribantumab in Preclinical NRG1 Fusion Models
- Results show seribantumab efficiently inhibited HER3 and the entire ERBB family signaling pathway and established a biologically effective dose range for tumors driven by an NRG1 fusion -
- Seribantumab is currently being evaluated in the tumor-agnostic Phase 2 CRESTONE trial for patients with any solid tumor harboring an NRG1 fusion -
News provided by
Share this article
Share this article
NEW YORK, April 6, 2021 /PRNewswire/ Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today the publication in ....

United States , David Rosen , Romel Somwar , Shawn Leland , Igor Odintsov , American Association For Cancer Research , Ladanyi Lab , Clinical Cancer Research , Senior Research Scientist , Memorial Sloan Kettering Cancer Center , Elevation Oncology , American Association , Cancer Research , Research Fellow , Objective Response Rate , ஒன்றுபட்டது மாநிலங்களில் , டேவிட் ரோஸன் , ஷான் லேலண்ட் , அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி , மருத்துவ புற்றுநோய் ஆராய்ச்சி , மூத்தவர் ஆராய்ச்சி விஞ்ஞானி , நினைவகம் ஸ்லோன் கெட்டரிங் புற்றுநோய் மையம் , உயரம் புற்றுநோயியல் , அமெரிக்கன் சங்கம் , புற்றுநோய் ஆராய்ச்சி , ஆராய்ச்சி சக ,